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Background: Danqi Pill (DQP), which contains Chinese herbs Salvia miltiorrhiza Bunge and Panax notoginseng, is
widely used in the treatment of myocardial ischemia (MI) in China. Its regulatory effects on MI-associated lipid
metabolism disorders haven’t been comprehensively studied so far. We aimed to systematically investigate the
regulatory mechanism of DQP on myocardial ischemia-induced lipid metabolism disorders.
Methods: Myocardial ischemia rat model was induced by left anterior descending coronary artery ligation. The rat
models were divided into three groups: model group with administration of normal saline, study group with
administration of DanQi aqueous solution (1.5 mg/kg) and positive-control group with administration of pravastatin
aqueous solution (1.2 mg/kg). In addition, another sham-operated group was set as negative control. At 28 days
after treatment, cardiac function and degree of lipid metabolism disorders in rats of different groups were
measured.
Results: Plasma lipid disorders were induced by myocardial ischemia, with manifestation of up-regulation of
triglyceride (TG), low density lipoprotein (LDL), Apolipoprotein B (Apo-B) and 3-hydroxy-3-methyl glutaryl coenzyme
A reductase (HMGCR). DQP could down-regulate the levels of TG, LDL, Apo-B and HMGCR. The Lipid transport
pathway, fatty acids transport protein (FATP) and Carnitine palmitoyltransferase I (CPTI) were down-regulated in
model group. DQP could improve plasma lipid metabolism by up-regulating this lipid transport pathway. The
transcription factors peroxisome proliferator-activated receptor α (PPARα) and retinoid X receptors (RXRs), which
regulate lipid metabolism, were also up-regulated by DQP. Furthermore, DQP was able to improve heart function
and up-regulate ejection fraction (EF) by increasing the cardiac diastolic volume.
Conclusions: Our study reveals that DQP would be an ideal alternative drug for the treatment of dyslipidemia
which is induced by myocardial ischemia.
Keywords: Lipid metabolism disorder, Myocardial ischemia, FATP-CPTI pathwayBackground
Coronary heart disease (CHD) is one of the major causes
of death worldwide [1,2]. CHD is the progress of the
coronary arteries stenosis, usually caused by atheroscler-
osis, which is the buildup of cholesterol and fatty
deposits on the inner walls of the arteries [3]. The
plaque formed in the artery could restrict blood flow to* Correspondence: wangwei26960@126.com
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unless otherwise stated.the heart muscles and cause myocardial ischemia. Lipid
peroxidation induced by lipid infiltration is considered
to be the main pathological mechanism of myocardial is-
chemia [4]. Some novel drugs targeting lipid metabolism
have been developed to treat or reduce the risk of myo-
cardial ischemia caused by CHD [5]. Statins, which are
HMG-CoA reductase inhibitors, are widely used for
their cholesterol-lowering properties and have been
proven to be able to reduce cardiovascular disease risk
[6]. Statins mainly reduce plasma levels of LDL, while
having little effect on TG [7]. Since 1970s, a number ofThis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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Among them, Danshen and Sanqi are the most fre-
quently prescribed [8-10]. Because they have definitive
curative effect and conform to pharmacopoeia standard
of quality control (Ministry of Health of the People’s
Republic of China), Danqi Pill (DQP), which is com-
posed of DanShen and Sanqi, was listed in Chinese
Pharmacopoeia 2010 as routine drug in the clinical
treatment of myocardial ischemia and impaired cardiac
function [11]. Danqi could also improve microcircula-
tion by exerting anti-platelet aggregation effect [12].
However, the effect of DQP on lipid metabolism signal-
ing pathway hasn’t been studied comprehensively so far.
Our previous study demonstrated that DQP could im-
prove heart function, partly via its regulation of ox-LDL
and arachidonic acid metabolism [13]. In this study, we
aim to investigate if DQP could regulate lipid metabol-
ism and prevent fat deposition in artery, thus interven-
ing the clinical course of MI in CHD.
Methods
CHD model preparation and animal grouping
A total of 80 pathogen-free male Sprague–Dawley (SD)
rats, weighing 220 ± 10 g, were selected and divided ran-
domly into sham-operated, model, DQP treatment and
Statin positive control group with 20 rats in each group.
The rats were purchased from Beijing Vital River Labora-
tory Animal Tchnology Co., Ltd. This study was carried
out in accordance with the China Physiological Society’s
“Guiding Principles in the Care and Use of Animal” and
approved by Animal Care Committee of Beijing University
of Chinese Medicine.
Myocardial ischemia model was induced in all but the
sham-operated group of rats by direct coronary ligation
as previously described [14,15]. In short, SD rats were
intubated and anaesthetized intraperitoneally with 1%
pentobarbital sodium at the dosage of 50mg/kg. Left
thoracotomy was then performed and the left anterior
descending coronary artery proximal to its main branch-
ing point was ligated with a 5–0 polypropylene suture
(Surgipro, CT, USA). One to two drops of lidocaine was
put on the surface of the rats’ hearts immediately after
ligation. SD rats in the sham-operated groups also
underwent thoracotomy but their coronary artery was
not ligated. Thorax was closed after thoracotomy and
ligation of the left anterior descending coronary artery.
Lidocaine of 0.1-0.2 ml and furosemide of 0.1-0.2 ml
were injected abdominally after the thorax was closed.
The rats were extubated when they could breathe suffi-
ciently. The DQP group was treated for 28 days by daily
oral gavage with dosages of 1.5 mg/kg of DQP aqueous
solution (Beijing university of Chinese Medicine, Beijing,
China, Series: 6128006). The positive control group was
also treated for 28 days by daily oral gavage of aqueouspravastatin solution (Bristol-Myers Squibb, China, Series:
H19980197) at the dosage of 1.2 mg/kg. Both the sham-
operated and model groups received the same volume of
saline water in the same way as the other two groups. 28
days after operation, blood samples were collected via ab-
dominal aorta puncture after all animals were anaesthe-
tized using pentobarbital sodium following an overnight
fast. After centrifugation, plasma was collected and stored
at −80 °C for further analysis. Left ventricle tissue was put
into liquid nitrogen for further analysis.
The DQP used in the present study was a Chinese pa-
tent medicine, manufactured by TongrenTang (Beijing,
China, Z11020471) using 2 Chinese herbs at a compos-
ition of 1:1(150 g S. miltiorrhiza bunge and 150 g P.
notoginseng). It strictly fulfils the China Pharmacopoeia
standard of quality control (Ministry of Health of the
People’s Republic of China Pharmacopoeia Committee,
2005). A voucher specimen (Series: 6128006) was kept in
the Beijing University of Chinese Medicine.
Echocardiographic assessment of heart function
Echocardiography was applied to measure cardiac func-
tion related parameters, including ejection fraction (EF),
left ventricular end-systolic diameter (LVEDs), left ven-
tricular end-diastolic diameter (LVEDd),and other indi-
cators including interventricular septum thickness at
end-systole (IVSs), interventricular septum thickness at
end-diastole (IVSd), the diastolic thickness of the LV
posterior wall (LVPWd), and LV posterior wall thickness
at end-systole (LVPWs). LV dimension (LVD) was mea-
sured by M model. Fractional shortening (FS%) was cal-
culated as: FS% = [(LVEDd − LVEDs)/LVEDd] × 100%.
Measurement of lipid metabolism indicators
The plasma was homogenized in saline which contains
heparin as anticoagulant at the concentration of 20 μL/
mL. The homogenate was centrifuged at 8000 × g for 10
min and supernatant was used for detection of plasma
indicators. Plasma Total Cholesterol (TC), TG, high dens-
ity lipoprotein (HDL) and LDL levels were measured by
automatic biochemical analyzer (HITACH17080, Japan)
following the instructions of the company.
Levels of Apolipoprotein A I (ApoA-I), Apolipoprotein
B (Apo-B), lipoprotein (a) (Lp(a)) and HMGCR were
quantified in duplicate using commercial ELISA kits
(Crystal Chem Inc., Downer’s Grove, USA). Each assay
was performed following their respective protocols.
Standards at a series of concentrations were run in par-
allel with the samples and the concentrations in the
samples were calculated in reference to the correspond-
ing standard curves.
Left ventricle homogenates were prepared from rats
for the analysis of protein levels. Equal amounts of pro-
tein extracts (20 mg) were separated by 12.5% or 15%
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trophoresis (Bio-Rad, CA, U.S.A.) and transferred to
nitrocellulose membranes electrophoretically (semidry
transfer). Membranes were blocked with 5% non-fat dry
milk in Tris-buffered saline (20 mM Tris, pH 7.6,
137 mM NaCl) with 0.1% Tween 20, washed, and
then incubated with primary antibody. Primary antibodies
employed included: goat polyclonal antiglyceraldehyde-
3-phosphate dehydrogenase (GAPDH) and anti-ApoAI
\FATP\CPTI\PPARα\RXR\NR2C2 (Abcam., U.S.A.). The
primary antibody was firstly incubated, and then the sec-
ondary antibodies (Santa Cruz Biotechnology Inc., CA, U.
S.A.) was added. After exposed by chemiluminescence de-
veloping agents, the protein levels and GAPDH in each
sample were evaluated. The gel was scanned and the band
densities were quantified. The other indicators were nor-
malized by the GAPDH band densities to determine their
concentrations.
Statistical analysis
ANOVA using SAS 9.2 statistical software (SAS Insti-
tute, NC, USA) was applied to evaluate between-group
differences in the outcome variables, follow-up least
significant differences (LSD) analysis verified these dif-
ferences were significant. P < 0.05 was considered sta-
tistically significant. Results were presented as mean
values with their corresponding standard deviations.
Results
Effects of DQP on parameters related to cardiac function
Twenty eight days after surgery, echocardiography
showed that EF and FS of rats in model group were sig-
nificantly lower than that in the sham-operated group
(Table 1, P < 0.01), indicating impaired cardiac function
of rats in the model group. LVEDd, LVEDs and LV mass
increased in the model group compared with those in
the sham-operated group, suggesting the development of
cardiac hypertrophy in this stage. After treatment with
DQP for 28 days, the EF and FS were up-regulated byTable 1 Cardiac function-related parameters in different grou
Group N Sham Mo
LV Mass (ug) 12 647.29 ± 206.658** 936
IVS;d (cm) 12 1.986 ± 0.316** 1.4
IVS;s(cm) 12 2.915 ± 0.592 ** 1.6
LVEDd(cm) 12 5.735 ± 0.656** 8.7
LVED;s(cm) 12 2.988 ± 0.829 ** 7.0
LVPWd(mm) 12 2.030 ± 0.441** 2.0
LVPWs(mm) 12 2.758 ± 0.598** 2.7
EF (%) 12 78.274 ± 10.514** 41.3
FS(%) 12 48.826 ± 10.557** 21.8
*P < 0.05, **P < 0.01, Levels in the model group were used as reference to calculate26.55% and 38.20% respectively, compared with those in
the model group. LVEDs was also improved significantly
after treatment with DQP (Table 1, P < 0.01). In the
positive control group, pravastatin showed no effect on
cardiac function-related parameters compared with
model group, as showed in Figure 1.
Effects of DQP on plasma HDL, LDL, TC and TG
Changes of plasma TC and TG levels are important indi-
cators of lipid metabolism disorders [16]. In this study,
plasma TG in the model group was up-regulated by
169.53% compared with that in the sham-operated group
(Table 2, P < 0.01). Plasma TC was also increased by
16.30% in the model group but the difference was not
statistically significant (P = 0.51). After treated with
DQP and pravastatin, TG level was reduced by 66.67%
and 39.54%, respectively (Table 2, P < 0.05). The level of
TC showed no significant change in either DQP or prav-
astatin group.
HDL and LDL are important lipid transportation lipo-
proteins. The balance between them is important for the
regulation of plasma level of lipid [17]. In this study,
Plasma HDL level decreased by 40.84% in the model
group compared with that in the sham-operated group
(P = 0.018). After treatment with DQP for 28 days, an
increase of HDL level was detected compared with the
model group (P = 0.04), which almost returned to the
level in sham-operated group. Pravastatin also up-
regulated HDL level as was shown in Table 2. In
addition, Plasma LDL increased by 98.25% in the model
group (P = 0.031) compared with the sham-operated
group and after treatment with DQP, the level was re-
duced by 64.73%. Pravastin could also reduce LDL level
but to a less degree compared with DQP (Table 2).
Effects of DQP on cardiac lipoprotein and HGMCR
To further investigate the mechanism by which DQP
regulates lipid metabolism, we detected changes of key
proteins in lipid metabolic pathway. Elisa results in thisps x  sð Þ
del Danqi pill Positive drug
.29 ± 203.356 803.33 ± 213.294 872.65 ± 137.586
02 ± 0.378 1.532 ± 0.500 1.190 ± 0.380
58 ± 0.684 2.050 ± 0.886 1.476 ± 0.539
41 ± 1.2054 7.777 ± 1.869 9.107 ± 1.138
59 ± 1.535 5.746 ± 2.502* 7.538 ± 1.519
12 ± 0.389 1.953 ± 0.392 1.852 ± 0.361
92 ± 0.481 2.254 ± 0.618 2.560 ± 0.618
88 ± 17.238 52.375 ± 24.421** 34.823 ± 14.849
82 ± 10.552 30.241 ± 17.328** 17.905 ± 8.367
P values.
Figure 1 Cardiac function detected by echocardiography. (A) Normal cardiac function including LVEF and LVFS in sham-operated group. (B)
Down-regulation of LVEF and LVFS in model group rats. (C) DQP can significantly up-regulate the EF and FS. (D) Positive Drug had no effects on
the cardiac function.
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centration was significantly lower than that in the
sham-operated group (Table 3, P = 0.033), while Apo-B
concentration increased by 141.67% (P = 0.003). After
treatment with DQP, level of ApoA-I was increased
and level of Apo-B was reduced significantly (P < 0.05).
Pravastatin could also down-regulate Apo-B signifi-
cantly and up-regulate ApoA-I to certain extentTable 2 Changes of plasma lipid indicators in different group
Group N TC(pg/ml)
Sham 12 99.17 ± 24.30
Model 12 115.33 ± 23.63
Danqi pill 12 119.30 ± 33.16
Positive Drug 12 105.56 ± 42.29
*P < 0.05, **P < 0.01,Levels in the model group were used as reference to calculate(Table 3). The levels of LP (a), another lipoprotein,
were not significantly different in all of four groups.
HMGCR is the most important target for the treat-
ment of hyperlipidemia. Statins are a group of HMGCR
inhibitors and verified to have efficacy for hyperlipidemia
by large scale clinical experiments [18]. In rats with
CHD, HMGCR was up-regulated by 98.25% compared
with that in sham-operated group. As a specific HMGCRs x  sð Þ
TG(pg/ml) HDL(pg/ml) LDL(pg/ml)
6.40 ± 2.30** 56.20 ± 20.03* 2.86 ± 1.07*
17.25 ± 5.56 33.25 ± 7.14 5.67 ± 1.53
5.75 ± 4.43** 52.75 ± 1.2 6* 2.00 ± 1.69**
10.43 ± 5.32* 41.50 ± 12.71 4.13 ± 2.30*
P values.
Table 3 Levels of Apolipoproteins and HMGCR in different groups x  sð Þ
Group N ApoA-I(pg/ml) Apo-B(pg/ml) LP(a) (pg/ml) HMGCR(ng/ml)
Sham 12 488.00 ± 3.04* 24.00 ± 13.02** 100.00 ± 12.35 2.86 ± 1.07**
Model 12 460.00 ± 9.33 58.00 ± 8.37 130.00 ± 42.43 5.67 ± 1.53
Danqi pill 12 482.86 ± 6.96* 16.67 ± 14.14** 102.00 ± 6.32 2.00 ± 1.69**
Positive Drug 12 471.11 ± 16.16 31.25 ± 17.27** 145.56 ± 87.91 1.13 ± 0.30*
*P < 0.05, **P < 0.01,Levels in the model group were used as reference to calculate P values.
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Meanwhile, DQP could also down-regulate HMGCR
level significantly (64.73%, P = 0.017). The Elisa results
were consistent with western blot results (Table 3 and
Figure 2).
Effects of DQP on FATP and CPTI proteins
Lipid metabolism disorders in CHD are closely associated
with defects in transportation and intake of fatty acids
[19]. Western blot analysis of cardiac FATP showed that
FATP level in the model group (0.49 ± 0.11) decreased by
50.61% compared with that in the sham-operated group
(1.00 ± 0.00, P = 0.017). Level of cardiac CPTI was also re-
duced by 33.33% (0.67 ± 0.18, P = 0.031), suggesting that
the ability of fatty acids intake by cardiac cells was im-
paired in rats with MI. After treatment with DQP, cardiacFigure 2 The myocardial concentration of ApoA-I and HMGCR
in different groups.The results showed that in rats with CHD,
plasma ApoA-I concentration was significantly lower than that in the
sham-operated group. In DQP group, level of ApoA-I was increased
significantly. Pravastatin could also up-regulate ApoA-I to certain
extent. The HMGCoA expression showed the reverse pattern in
different groups. * P < 0.05, * * P < 0.01. Levels in the model group
were used as reference to calculate P values.FATP and CPTI levels increased by 95.64% (0.97 ± 0.13)
and 41.68% (0.94 ± 0.24) respectively, indicating that DQP
could promote the intake of fatty acids by cardiac cells.
Pravastatin increased the level of CPTI but had no signifi-
cant effect on FATP (Figure 3).
Effects of DQP on PPARα-RXR pathway regulation
PPARα-RXR pathway plays an important role in regu-
lating fatty acids metabolism in cardiac cells [20,21]. In
the model group of this study, the levels of PPARα and
RXR decreased by 52.18% (0.48 ± 0.17) and 80.86%
(0.19 ± 0.08) respectively compared with those in
sham-operated group (P < 0.01). The level of NR2C2
(2.32 ± 0.216), which is a transcription inhibitor of
PPARα-RXR pathway, increased significantly, further
suppressing the activation of PPARα-RXR pathway
(Figure 4, P < 0.001). P450 oxidase is a key enzyme in
the oxidation process of fatty acids and a reduced level
(0.43 ± 0.04) was observed in the model group (Figure 4,
P = 0.044). After treatment with DQP, PPARα-RXR path-
way was up-regulated, illustrated by an increased level ofFigure 3 The myocardial concentration of FATP and CPTI. The
results showed that FATP in the model group decreased compared
with that in the sham-operated group. Level of Cardiac mitochondrial
CPTI was also reduced. In DQP group, both the cardiac FATP and CPTI
levels increased. Pravastatin increased the level of CPTI but had no
significant effect on FATP. *P < 0.05, **P < 0.01. Levels in the model
group were used as reference to calculate P values.
Figure 4 The myocardial concentration of PPARα, RXR, NR2C2
and P450. The results showed that the levels of PPARα and RXR
decreased compared with sham-operated group. The level of NR2C2
increased significantly. A reduction level of P450 was observed in
the model group. In DQP group, PPARα-RXR pathway was up-regulated,
together with decreased level of NR2C2. P450 level was also increased.
Pravastatin had similar efficacy on all these indicators as DQP, except for
PPARα.*P < 0.05, **P < 0.01. Levels in the model group were used as
reference to calculate P values.
Wang et al. BMC Complementary and Alternative Medicine  (2015) 15:28 Page 6 of 8PPARα (1.09 ± 0.23) and RXR (0.92 ± 0.22) together with
decreased level of NR2C2 (1.25 ± 0.15). P450 oxidase level
(1.10 ± 0.25) was also increased in DQP group, thus pro-
moting the degradation of lipids in cardiac cells [22,23].
Pravastatin had similar efficacy on all these indicators as
DQP, except for PPARα.
Discussion
According to lipid infiltration theory, lipid metabolism
disorder is one of the major pathological mechanisms of
myocardial ischemia induced by coronary heart disease
[24,25]. However, few studies have been carried out to
investigate if myocardial ischemia can cause lipid metab-
olism disorders and raise the plasma lipid directly. The
verification of this causation would have important clin-
ical implications: even if myocardial ischemia is not
caused by high plasma lipid, the plasma lipid should also
be monitored closely in case that the symptom was ag-
gravated by lipid metabolism disorders. Our previous
study indicated that myocardial ischemia could induce
lipid metabolism disorders in swine ischemia model
[13]. We observed that the levels of plasma ox-LDL,
LDL and VLDL were up-regulated. Renin-angiotensin-
aldosterone system was also activated together with lipid
disorders [13]. However, the mechanism of lipid me-
tabolism disorder hasn’t been illustrated so far. In
this study, we aimed to study the mechanism of fatty
acids metabolism disorder induced by pure myocardialischemia in a comprehensive perspective of “circula-
tion, intake and degradation” of fatty acids in myocar-
dial ischemia models. We also aimed to explore the
mechanism by which DQP regulates lipid metabolism
in ischemia heart.
This study showed that in model rats with myocardial
ischemia, the level of “good” lipoprotein HDL was
down-regulated, while the level of “bad” LDL was in-
creased by 98.3%. TG level was up-regulated, indicating
that plasma lipid metabolism disorder was induced in
our myocardial ischemia models. Under normal condi-
tions, 70% of the energy supply of the normal cardiac
cells comes from β oxidation of lipid [26]. Fatty acids in
plasma are transported into cardiac cells by FATP on the
membrane of cardiac cells. CPTI, a mitochondrial trans-
membrane enzyme, further transfers fatty acid into
mitochondria for β-oxidation. Activation of CPTI is
thought to be rate limiting for fatty acid entry into the
mitochondria for oxidation [27,28]. Under the condition
of cardiac ischemia, production of ATP is decreased.
Tryglyceride is mobilized into plasma, degraded into gly-
cerol and fatty acids and further oxidized to provide en-
ergy for cardiac cells [29]. Our study showed that in
model rats with myocardial ischemia, the fatty acids
transportation pathway was down-regulated, illustrated
by decreased expression of FATP which uptakes free
fatty acids from circulation. Besides, the expression of
CPTI was significantly down-regulated, so the transpor-
tation of fatty acids into mitochondria for β-oxidation
was also compromised. Furthermore, the transcription
factors PPARα and RXR which could promote β oxida-
tion of fatty acids, were also decreased in the myocardial
ischemia model [20,30]. The degradation of fatty acids in
cardiac cells was further down-regulated by increased
expression of the metabolism pathway inhibitor NR2C2
[31]. Moreover, P450, which can utilize fatty acids as
substrates to produce PPARα ligands, also decreased
[32,33]. In summary, the deregulation of FATP, CPTI
and PPARα could be the cause of fatty acids metabolism
disorders in myocardial ischemia model.
DQP is a widely prescribed medicine for myocardial
ischemia associated with coronary heart disease and has
definitive efficacy [8]. It can prevent the aggregation of
platelets and improve microcirculation [12]. However,
the direct and comprehensive effects of DQP on fatty
acids metabolism haven’t been reported yet. Previous
study has suggested that Danshen, a component of DQP,
could improve plasma lipid metabolism in hyperlipid-
emic rats [34]; Salvianolicacid IIA could regulate plasma
lipid by improving the level of HDL in patients with cor-
onary atherosclerosis[35]; Panax notoginseng saponins
could improve lipid metabolism in aortic endothelial
cells by inducing the expression of liver X receptor alpha
(LXR-α) [36]. In this study, we investigated the effect of
Figure 5 The potential mechanism of DQP regulating the lipid disorder induced by myocardial ischemia.
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plore its potential pharmacological mechanism.
Our study showed that DQP was able to regulate
HDL and LDL levels, thus improving lipid metabolism
in rats with MI. 28 days after treatment with DQP,
FATP-CPTI pathway was activated and the level of
PPARα and RXR increased significantly, almost back to
normal level as that in the sham-operated group.
PPARα–RXR are heterodimeric transcription factors
that regulate lipid metabolism, by promoting β-
oxidation of fatty acids and synthesis of Apo A-I and
LPL, lowering TG and LDL levels and raising HDL
level [21,30,37-39]. PPARα agonists, such as fibrates,
have been used widely for the treatment of dyslipid-
emia [39]. DQP may activate PPARα in the similar way
as fibrates. DQP also down-regulated the level of
PPARα inhibitor NR2C2, further activating the tran-
scriptional effect of PPARα [31]. Finally, DQP also can
up-regulate the level of P450, further increasing the ac-
tivity of PPARα.
Those results suggest that DQP could promote the
intake and breakdown of free fatty acids by effectively
activating FATP-CPTI pathway and relieving the sup-
pression effect of NR2C2 on PPARα pathway (Figure 5).
The lipid metabolism disorder induced by myocardial
ischemia in model rats could be greatly improved by
DQP administration.
Pravastatin was used as positive control in this study.
Statins are used as the first-line drugs for the treatment
of dyslipidemia, by inhibiting the enzyme HMG-CoA re-
ductase [30]. The results of this study showed that DQP
could regulate lipid metabolism as effectively as prava-
statin. Furthermore, DQP was able to improve heart func-
tion and up-regulate ejection fraction by increasing the
cardiac diastolic volume. So our study reveals that DQP
would be an ideal alternative drug for the treatment of
dyslipidemia which is induced by myocardial ischemiaConclusions
In conclusion, we not only explored the pathological
mechanism of lipid metabolism disorder induced by
myocardial ischemia in MI rats model, but also investi-
gated the regulatory efficacy of DQP on lipid metabol-
ism. This study provides new insights into ways for
clinical management of lipid metabolic disorders in-
duced by MI.Limitation
There are a few limitations in our study. Firstly, even
though the dyslipidemia model induced by myocardial
ischemia has been created in different species such as
swine and rats, more experiments are still needed to fur-
ther validate this result. In particular, more clinical data
needs to be analyzed to support the result. Secondly, we
focused on lipid metabolism disorders induced by myo-
cardial ischemia only in myocardial tissues and plasma.
We didn’t analyze lipid metabolism in other tissues such
as liver and intestines. More studies will be carried out
to comprehensively analyze lipid disorders induced by
myocardial ischemia in other tissues.Competing interests
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